× ×ª×× × ×ª×¨×פ×
××רש×
| ××× ×× ×× × ×ספ××
|
|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
L01EX
Other protein kinase inhibitors
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
פ××× - PER OS
|
| צ×רת ××× ××
|
קפס××× ×§×©×××, HARD CAPSULE
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
-LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/H?rthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).-LENVIMA is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.LENVIMA is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 21/01/2016
|
×××××ת ×ס×
-
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×ש×××× ×¢× Pembrolizumab ×××פ×× ×סר×× ×¨×× ×תק×× ×× ×××ר ××××× ×©××× pMMR (mismatch repair proficient), ש××××ª× ×תק××× ××××× ×× ×××ר ×§× ××פ×× ××× ×× ××תר ש××× ××××תרפ×× ×××ססת פ×××× ×× ×××× ××× × ×××¢××ת ×× ×ת×× ×× ××§×¨× ×ת ×¢× ×¤××× ×¦××× ×§×ר×××××. ××××× ××××ª× ×ª××× ××××× ××××ת ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors. ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××× ×§×××××× ××××¤× ×××× ×§×××××× ××× ×§×××××ת.
|
17/03/2024 |
××× ×§×××××× |
|
סר×× ×¨×× ×תק××, pMMR (mismatch repair proficient) |
|
| סר×× ×××× ×תק×× ×× ×ר××¨×ª× ××§× ××פ×× ×¨×ש×× Pembrolizumab ×ש×××× ×¢× Axitinib ×× ×ש×××× ×¢× Lenvatinib ×××××× ××ר×ת ס×××× poor ×× intermediate. ××××× ××××ª× ×××× ××××× ×××× ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors, ×שר ת××× ×××× ×ª× ××ש×× ××× ×××× ×¢× ×ª×ש×ר ×××שפ×ת ××¢××× ××ר×××× ×§×× ××. |
03/02/2022 |
××× ×§×××××× |
|
RCC, Renal cell carcinoma |
|
| סר×× ×פ××צ××××¨× ×תק×× ×× ×× × ×ª×× ×××××× ×©××¨× ×§×××× ××פ×× ×¡×ס××× ××××ת×. ××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×תר××¤× ××ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× â Lenvatinib, Sorafenib |
16/01/2019 |
××× ×§×××××× |
|
Hepatocellular carcinoma, HCC |
|
| סר×× ×××× ×תק×× ×× ×ר×רת×, ×××ר ××©× ×××פ×× ×§××× |
11/01/2018 |
××× ×§×××××× |
|
Renal cell carcinoma, advanced |
|
| סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ××××ת ×תר×ס ×ס×× DTC (Differentiated (papillary / follicular / Hurthle cell) thyroid carcinoma) ×¢××× ×××× ×¨××××ק×××× |
21/01/2016 |
××× ×§×××××× |
|
DTC, Differentiated thyroid cancer |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×תר××¤× ×ª×× ×ª× ×××פ×× ××קר×× ××××:
- ××פ×× ×××××× ×××ר×× ×ס××××× ×סר×× ×תק×× ×ק××× ×× ×ר××¨×ª× ×©× ××××ת ×תר×ס ×ס×× DTCâ (papillary / follicular / Hurthle Differentiated cell thyroid carcinoma) ×¢××× ×××× ×¨××××ק××××.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××£ ×××× ×ר×× ×× ×¨××¤× ××××× ××× ××קר×× ××××××
- סר×× ×××× ×תק×× ×× ×ר×רת×, ×××ר ××©× ×××פ×× ×§×××.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××ר×××××× ××××¤× ×××ר×××××× ××× ×§×××××ת
- סר×× ×פ××צ××××¨× ×תק×× ×× ×× × ×ª×× ×××××× ×©××¨× ×§×××× ××פ×× ×¡×ס××× ××××ת×.
××××× ××××ª× ×××× ××××× ×××× ×××פ×× ×תר××¤× ××ת ×××× ××תר×פ×ת ××פ×ר××ת ×××× - Lenvatinib, Sorafenib.
××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§××××××
- ×ש×××× ×¢× Pembrolizumab ×××פ×× ×סר×× ×¨×× ×תק×× ×× ×××ר ××××× ×©××× pMMR (proficient mismatch repair), ש××××ª× ×תק××× ××××× ×× ×××ר ×§× ××פ×× ××× ×× ××תר ש××× ××××תרפ×× ×××ססת פ×××× ×× ×××× ××× × ×××¢××ת ×× ×ת×× ×× ××§×¨× ×ת ×¢× ×¤××× ×¦××× ×§×ר×××××.
××××× ××××ª× ×ª××× ××××× ××××ת ×תר××¤× ××ת ×××× ×תר×פ×ת ××שת××××ת ××שפ×ת ×-Checkpoint inhibitors
- ××ª× ×תר××¤× ×××××¨× ×××¢×©× ××¤× ××¨×©× ×©× ×¨××¤× ××××× ×××× ×§×××××× ×× ×¨××¤× ××××× ×××× ×§×××××× ××××¤× ×××× ×§×××××× ××× ×§×××××ת.
|
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
ת××× ×ª ×ר×××
ת×ר×× ×¢××××: 12/02/24
EISAI
×× ××××× - Lenvima
true
השינוי האחרון נעשה בֹ־18 ביולי 2025 ב־05:08
